Kathleen N Moore

Summary

Affiliation: University of Oklahoma Health Sciences Center
Country: USA

Publications

  1. Moore K, Secord A, Geller M, Miller D, Cloven N, Fleming G, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;: pubmed publisher
    ..We identified no new safety signals. Our data support expansion of the treatment indication for poly(ADP-ribose) polymerase inhibitors to include patients with HRD-positive ovarian cancer beyond those with BRCA mutations. Tesaro. ..
  2. Gillen J, Richardson D, Moore K. Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development. Curr Oncol Rep. 2019;21:22 pubmed publisher
    ..Further evaluation of these therapies, however, is warranted to better understand their optimal clinical utility. ..
  3. Moore K, Chan J, Secord A, Patel M, Callahan T, Guo W, et al. Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. Cancer Chemother Pharmacol. 2019;83:717-726 pubmed publisher
    ..Niraparib administration at the recommended daily dose of 300 mg for EOC is not associated with clinically relevant alteration of ECGs, including QTc prolongation. ..
  4. Moore K, Pignata S. Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage. Int J Gynecol Cancer. 2019;: pubmed publisher
    ..There are two co-primary efficacy endpoints: investigator-assessed progression-free survival and overall survival. 1300 patients. April 2020. NCT03038100. ..
  5. Boardman C, Brady W, Dizon D, Kunos C, Moore K, Zanotti K, et al. A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecolog. Gynecol Oncol. 2018;151:202-207 pubmed publisher
    ..The predominant grade 3 or 4 acute toxicities were hematologic. There were no grade 5 events. Extended field chemoRT followed by paclitaxel 135 mg/m2 and carboplatin AUC 5 is feasible in women with LACC and positive PAN. ..
  6. Moore K, O Malley D, Vergote I, Martin L, Gonzalez Martin A, Malek K, et al. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018;151:46-52 pubmed publisher
    ..Further evaluation of this combination in a randomized fashion is warranted. ..
  7. McMeekin D, Sill M, Walker J, Moore K, Waggoner S, Thaker P, et al. A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015;138:36-40 pubmed publisher
    ..Based on the high rate of completing 6cycles of therapy, low rates of neuropathy, and promising PFS, further study of IP therapy in endometrial cancer is warranted. ..
  8. Moore K, Birrer M. Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations. Oncologist. 2018;23:697-703 pubmed publisher
    ..This review discusses the differences between the two formulations, dose determination, and guidance for use of olaparib tablets by patients with OC. ..
  9. Brown J, Naumann R, Brady W, Coleman R, Moore K, Gershenson D. Clinical trial methodology in rare gynecologic tumor research: Strategies for success. Gynecol Oncol. 2018;149:605-611 pubmed publisher
    ..Strategies for effective study of rare gynecologic cancers must be implemented when designing clinical trials for these patients. ..

More Information

Publications32

  1. request reprint
    Moore K, Herzog T, Lewin S, Giuntoli R, Armstrong D, Rocconi R, et al. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol. 2007;105:299-303 pubmed
    ..Because of its ease of administration and improved toxicity profile, CT should be considered in the treatment of advanced, recurrent or progressive cervical cancer. ..
  2. request reprint
    Moore K, Moxley K, Fader A, Axtell A, Rocconi R, Abaid L, et al. Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary. Gynecol Oncol. 2007;107:398-403 pubmed
    ..This should reassure clinicians that treatment of PCFT should mirror that of OC and that PCFT should be included in clinical trials. ..
  3. Moore K, Sill M, Tenney M, Darus C, Griffin D, Werner T, et al. A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial. Gynecol Oncol. 2015;138:513-8 pubmed publisher
    ..Trebananib has insufficient single agent activity in recurrent EC to warrant further investigation at this dose/schedule. ..
  4. Gillen J, Gunderson C, Greenwade M, Rowland M, Ruskin R, Ding K, et al. Contribution of age to clinical trial enrollment and tolerance with ovarian cancer. Gynecol Oncol. 2017;145:32-36 pubmed publisher
    ..Further research is needed to identify the mechanisms which contribute to the inequality that age imposes on outcomes. ..
  5. Gunderson C, Ding K, Dvorak J, Moore K, McMeekin D, Benbrook D. The pro-inflammatory effect of obesity on high grade serous ovarian cancer. Gynecol Oncol. 2016;143:40-45 pubmed publisher
    ..Differences in survival and platinum sensitivity were not noted. Future studies are warranted to determine whether obesity may be a modifiable risk factor for poorer outcomes due to differing immune response. ..
  6. Landrum L, Brady W, Armstrong D, Moore K, DiSilvestro P, O Malley D, et al. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016;140:204-9 pubmed publisher
    ..o. b.i.d. in women with recurrent, platinum-sensitive ovarian cancer. With bevacizumab, DLTs were noted in 9 out of 12 patients. Lower doses of veliparib will need to be considered when given in combination with platinum-based therapies. ..
  7. Moore K, Zhang Z, Agarwal S, Burris H, Patel M, Kansra V. The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer. Cancer Chemother Pharmacol. 2018;81:497-503 pubmed publisher
    ..Adverse events were similar between conditions. A high-fat meal did not impact the PK profile of niraparib, indicating that niraparib can be taken with or without food. Niraparib was safe and well-tolerated. ..
  8. Gunderson C, Rowland M, Wright D, Andrade K, Mannel R, McMeekin D, et al. Initiation of a formalized precision medicine program in gynecologic oncology. Gynecol Oncol. 2016;141:24-8 pubmed publisher
    ..Longer-term follow up will be required to determine the success of this strategy. ..
  9. Moore K, Mannel R. Is the NCI MATCH trial a match for gynecologic oncology?. Gynecol Oncol. 2016;140:161-6 pubmed publisher
    ..This review article will discuss the types of novel trial designs that led to the development and launch of the NCI MATCH. ..
  10. Moore K, Mirza M, Matulonis U. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. Gynecol Oncol. 2018;149:214-220 pubmed publisher
  11. Gunderson C, Matulonis U, Moore K. Management of the toxicities of common targeted therapeutics for gynecologic cancers. Gynecol Oncol. 2018;148:591-600 pubmed publisher
  12. Moore K, Monk B. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer. Oncologist. 2016;21:954-63 pubmed publisher
    ..This report summarizes a practical approach to supportive care for patients receiving olaparib therapy. ..
  13. Ahsen M, Boren T, Singh N, Misganaw B, Mutch D, Moore K, et al. Sparse feature selection for classification and prediction of metastasis in endometrial cancer. BMC Genomics. 2017;18:233 pubmed publisher
    ..25%). Results indicate that the evaluation of the quantitative sparse-feature classifier proposed here in clinical trials may lead to significant improvement in the prediction of lymphatic metastases in endometrial cancer patients. ..
  14. CRIM A, Rowland M, Ruskin R, Dvorak J, Greenwade M, Walter A, et al. Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women. Gynecol Oncol. 2017;146:268-272 pubmed publisher
    ..IP CT appears well tolerated and effective among select older patients and is likely under-utilized outside of clinical trials. ..
  15. Moore K, Tritchler D, Kaufman K, Lankes H, Quinn M, Van Le L, et al. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017;147:396-401 pubmed publisher
    ..The SNP's identified in this GWAS study will require validation and these preliminary findings may lead to identification of novel pathways and biomarkers. ..
  16. Martin L, Konner J, Moore K, Seward S, Matulonis U, Perez R, et al. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017;147:402-407 pubmed publisher
    ..Regardless of the tissue source analyzed, higher FRα expression was associated with greater antitumor activity. ..
  17. Thaker P, Brady W, Lankes H, Odunsi K, Bradley W, Moore K, et al. A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary perit. Gynecol Oncol. 2017;147:283-290 pubmed publisher
    ..GEN-1 in combination with PLD has encouraging clinical benefit and biological activity in recurrent or persistent EOC and warrants further investigation with escalating doses of GEN-1. ..
  18. Greenwade M, Moore K, Gillen J, Ding K, Rowland M, Crim A, et al. Factors influencing clinical trial enrollment among ovarian cancer patients. Gynecol Oncol. 2017;146:465-469 pubmed publisher
    ..Increasing age was associated with non-participation. Modifiable barriers must be overcome so that trial enrollment can better reflect true EOC demographics. ..
  19. Grabosch S, Tseng G, Edwards R, Lankes H, Moore K, Odunsi K, et al. Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2017;146:137-145 pubmed publisher
    ..Flow cytometry does not adequately capture biomarker fluctuations. As a proof of principle study, this trial provides evidence that sampling the peritoneal cavity can be adapted for biomarker analysis. ..
  20. Jandial D, Brady W, Howell S, Lankes H, Schilder R, Beumer J, et al. A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017;145:236-242 pubmed publisher
    ..IP administration of this novel combination was feasible and showed promising activity in this phase I trial of heavily pre-treated women with ovarian cancer. Further evaluation of this IP combination should be conducted. ..
  21. Moore K, Java J, Slaughter K, Rose P, Lanciano R, DiSilvestro P, et al. Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. Gynecol Oncol. 2016;143:294-301 pubmed publisher
    ..Older patients, had higher rates of incomplete brachytherapy which is not explained by collected toxicity data. Age did not adversely impact completion of chemotherapy and radiation or toxicities. ..
  22. Gunderson C, Java J, Moore K, Walker J. The impact of obesity on surgical staging, complications, and survival with uterine cancer: a Gynecologic Oncology Group LAP2 ancillary data study. Gynecol Oncol. 2014;133:23-7 pubmed publisher
    ..To determine the association of body mass index (BMI) on complications, recurrence, and survival in GOG LAP2, a randomized comparison of laparoscopic versus open staging in clinically early stage uterine cancer (EC)...
  23. request reprint
    Moore K, Gold M, McMeekin D, Zorn K. Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma. Gynecol Oncol. 2007;106:498-501 pubmed
    ..To evaluate the rate of vesicovaginal fistula formation and mortality in women with Stage IVA cervical carcinoma...